scholarly journals Genetic and Environmental Risk Factors for Age-Related Macular Degeneration in Persons 90 Years and Older

2014 ◽  
Vol 55 (3) ◽  
pp. 1842 ◽  
Author(s):  
Lebriz Ersoy ◽  
Tina Ristau ◽  
Moritz Hahn ◽  
Marcus Karlstetter ◽  
Thomas Langmann ◽  
...  
PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132771 ◽  
Author(s):  
Se Joon Woo ◽  
Jeeyun Ahn ◽  
Margaux A. Morrison ◽  
So Yeon Ahn ◽  
Jaebong Lee ◽  
...  

2015 ◽  
Vol 9s2 ◽  
pp. JEN.S25513 ◽  
Author(s):  
Katie L. Pennington ◽  
Margaret M. Deangelis

Degenerative retinal diseases, such as glaucoma, age-related macular degeneration, and diabetic retinopathy, have complex etiologies with environmental, genetic, and epigenetic contributions to disease pathology. Much effort has gone into elucidating both the genetic and the environmental risk factors for these retinal diseases. However, little is known about how these genetic and environmental risk factors bring about molecular changes that lead to pathology. Epigenetic mechanisms have received extensive attention of late for their promise of bridging the gap between environmental exposures and disease development via their influence on gene expression. Recent studies have identified epigenetic changes that associate with the incidence and/or progression of each of these retinal diseases. Therefore, these epigenetic modifications may be involved in the underlying pathological mechanisms leading to blindness. Further genome-wide epigenetic studies that incorporate well-characterized tissue samples, consider challenges similar to those relevant to gene expression studies, and combine the genome-wide epigenetic data with genome-wide genetic and expression data to identify additional potentially causative agents of disease are needed. Such studies will allow researchers to create much-needed therapeutics to prevent and/or intervene in disease progression. Improved therapeutics will greatly enhance the quality of life and reduce the burden of disease management for millions of patients living with these potentially blinding conditions.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maiko Maruyama-Inoue ◽  
Tatsuya Inoue ◽  
Shaheeda Mohamed ◽  
Yoko Kitajima ◽  
Shoko Ikeda ◽  
...  

AbstractThe purpose of this study was to report the incidence of elevated intraocular pressure (IOP) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) in Japanese patients with age-related macular degeneration (AMD). A retrospective study of chart review of patients who underwent ≥ 10 intravitreal anti-VEGF injections between April 2009 and December 2019 was conducted. Elevated IOP was defined as IOP ≥ 25 mmHg at one visit. Cases with elevated IOP resulting from IVI were identified. Furthermore, the association between elevated IOP and some parameters, as the risk factors that influence elevated IOP, was investigated. A total of 402 eyes of 370 patients were included in this study. Twenty-eight eyes of 26 patients (7.0%) were identified as cases with elevated IOP after IVI. The mean time of elevation after baseline was 50.6 ± 26.5 months. History of glaucoma (p = 0.021; odds ratio, 5.85), treatment modality (p = 0.019; odds ratio, 6.32), and total number of injections (p = 0.003; odds ratio, 1.03) were significantly associated with elevated IOP. A late complication of elevated IOP is associated with IVI in patients with AMD. Particularly, history of glaucoma and treat and extend regimen with frequent injections were found to be risk factors of elevated IOP.


2021 ◽  
Vol 22 (3) ◽  
pp. 1170
Author(s):  
Arunbalaji Pugazhendhi ◽  
Margaret Hubbell ◽  
Pooja Jairam ◽  
Balamurali Ambati

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD’s progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.


2020 ◽  
Vol 4 (7) ◽  
pp. 662-672 ◽  
Author(s):  
Usha Chakravarthy ◽  
Clare C. Bailey ◽  
Peter H. Scanlon ◽  
Martin McKibbin ◽  
Rehna S. Khan ◽  
...  

Ophthalmology ◽  
2014 ◽  
Vol 121 (9) ◽  
pp. 1766-1772 ◽  
Author(s):  
Fridbert Jonasson ◽  
Diana E. Fisher ◽  
Gudny Eiriksdottir ◽  
Sigurdur Sigurdsson ◽  
Ronald Klein ◽  
...  

2013 ◽  
Vol 28 (5) ◽  
pp. 445-446 ◽  
Author(s):  
Giuseppe La Torre ◽  
Elena Pacella ◽  
Rosella Saulle ◽  
Guglielmo Giraldi ◽  
Fernanda Pacella ◽  
...  

2011 ◽  
Vol 152 (3) ◽  
pp. 385-395 ◽  
Author(s):  
Farzana Choudhury ◽  
Rohit Varma ◽  
Roberta McKean-Cowdin ◽  
Ronald Klein ◽  
Stanley P. Azen

Sign in / Sign up

Export Citation Format

Share Document